EAM
AGTC

Eukles Asset Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Eukles Asset Management’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed – – 229
2022
Q3 		$0 Hold
1
– – ﹤0.01% 226
2022
Q2 		$0 Hold
1
– – ﹤0.01% 224
2022
Q1 		$0 Hold
1
– – ﹤0.01% 230
2021
Q4 		$0 Hold
1
– – ﹤0.01% 233
2021
Q3 		$0 Hold
1
– – ﹤0.01% 242
2021
Q2 		$0 Hold
1
– – ﹤0.01% 247
2021
Q1 		$0 Hold
1
– – ﹤0.01% 214
2020
Q4 		$0 Hold
1
– – ﹤0.01% 169
2020
Q3 		$0 Buy
+1
New +$5 ﹤0.01% 176

Eukles Asset Management's AGTC Position: Q4 2022 in Review

Eukles Asset Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 1 share.

Eukles Asset Management first reported a position in AGTC in Q3 2020 and held it in 9 quarters. The position peaked at $0 in Q3 2022. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.

  • Eukles Asset Management reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
  • Eukles Asset Management sold 1 Applied Genetic Technologies Corporation share in Q4 2022.
  • Eukles Asset Management first reported a position in Applied Genetic Technologies Corporation in Q3 2020 and held it in 9 quarters.
  • Eukles Asset Management's Applied Genetic Technologies Corporation position peaked at $0 in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.

Based on Eukles Asset Management's 13F filing for Q4 2022, filed 27 Jan 2023.